KING ANDREW JAMES (Head of Renal Discovery) sold 5.7% of their position (1.17K shares) of CHINOOK THERAPEUTICS, INC. on the open market
Open‑market sale worth $45.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/1/2023ACC: 0001209191-23-044071
Officer· Head of Renal Discovery
Since Oct 2020
-1.17K
Net shares
Net seller
$45.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
3.33K acquired · 4.50K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+3.33K
Price / share
—
Trade value
—
% of position
19.6%
7/29/2023
16.99K→20.32K
Common Stock
Direct
Shares
−1.17K
Price / share
$39.03
Trade value
$45.59K
% of position
5.7%
8/1/2023
20.32K→19.16K
Total
Net shares
+2.17K
Net value
-$45.59K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/29/2023 | M · Option Exercise | +3.33K | — | — | 19.6% | 16.99K | 20.32K |
| Common Stock Direct | 8/1/2023 | S · Sale | −1.17K | $39.03 | $45.59K | 5.7% | 20.32K | 19.16K |
| Total | +2.17K | -$45.59K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
3.33K shares
Shares
−3.33K
Strike price
Held after
6.67K
Exercisable
—
7/29/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock3.33K shares | 7/29/2023 | M · Option Exercise | −3.33K | — | 6.67K |